Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H15ClNO4.Na.3H2O |
Molecular Weight | 433.815 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[Na+].COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC([O-])=O
InChI
InChIKey=UHYAQBLOGVNWNT-UHFFFAOYSA-M
InChI=1S/C19H16ClNO4.Na.3H2O/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;;;;/h3-9H,10H2,1-2H3,(H,22,23);;3*1H2/q;+1;;;/p-1
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11906281 |
3.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20503989 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4681 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23432095 |
100.0 nM [IC50] | ||
Target ID: CHEMBL1835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2547071 |
100.0 nM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
|||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2369 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7762 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.22 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.152Nausea (mild) Anorexia (mild) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 11 patient) Sources: Pruritus (below serious, 5 patients) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 34 patients) Sources: Vomiting (below serious, 11 patient) Constipation (below serious, 8 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Deep vein thrombosis, Headache... Other AEs: Deep vein thrombosis (serious, 1 patient) Sources: Headache (below serious, 13 patients) Pruritus (below serious, 1 patient) Presyncope (below serious, 5 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Sources: Vomiting (below serious, 12 patients) Constipation (below serious, 7 patients) Post procedural haemorrhage (below serious, 7 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 12 patients) Sources: Pruritus (below serious, 3 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Other AEs: Headache, Vomiting... Other AEs: Headache (below serious, 17 patients) Sources: Vomiting (below serious, 9 patients) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (serious) Sources: Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (grade 3-5) Ulceration (grade 3-5) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Other AEs: Gingival bleeding, Application site pruritus... Other AEs: Gingival bleeding (below serious, 1 patient) Sources: Application site pruritus (below serious, 1 patient) Inflammation (below serious, 1 patient) Nasopharyngitis (below serious, 1 patient) Ligament sprain (below serious, 1 patient) Rash (below serious, 2 patients) Drug eruption (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | Disc. AE | 0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Anorexia | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Nausea | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Headache | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Pruritus | below serious, 5 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Nausea | below serious, 34 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Constipation | below serious, 8 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Pruritus | below serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Headache | below serious, 13 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Presyncope | below serious, 5 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Deep vein thrombosis | serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 12 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Nausea | below serious, 36 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Constipation | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Post procedural haemorrhage | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 12 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Pruritus | below serious, 3 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 17 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Vomiting | below serious, 9 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Bleeding | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Myocardial infarction | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation of intestine | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation stomach | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Stroke | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Ulceration | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Cardiac thrombosis | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Gastrointestinal disorder NOS | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Application site pruritus | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Drug eruption | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Gingival bleeding | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Inflammation | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Ligament sprain | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Nasopharyngitis | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Rash | below serious, 2 patients | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Aspirin sensitivity: other drugs. | 1975 Feb |
|
[Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis]. | 1975 Feb |
|
[Evaluation of the effects of some non-steroid anti-inflammatory agents on the gastric mucosa]. | 1976 Jul 7 |
|
[Intrahepatic cholestasis following treatment with penicillamine D and indomethacine]. | 1976 May 28 |
|
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem. | 1979 Sep 15 |
|
Plaunotol prevents indomethacin-induced gastric mucosal injury in rats by inhibiting neutrophil activation. | 1999 Apr |
|
Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. | 1999 Dec |
|
Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. | 1999 Dec |
|
Prostaglandin-independent anovulatory mechanism of indomethacin action: inhibition of tumor necrosis factor alpha-induced sheep ovarian cell apoptosis. | 1999 Dec |
|
Activation of apoptotic caspase-3 and nitric oxide synthase-2 in gastric mucosal injury induced by indomethacin. | 1999 Feb |
|
[Psychiatric side effects of non-steroidal anti-inflammatory agents]. | 1999 Jan-Feb |
|
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats. | 1999 Jul |
|
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. | 1999 Jul |
|
Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or up-regulation of c-myc. | 1999 Jul 1 |
|
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. | 1999 Jun |
|
Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major. | 1999 May |
|
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents. | 1999 Nov |
|
Effect of anti-CD11b (alphaM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats. | 1999 Nov |
|
Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. | 1999 Nov |
|
Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. | 1999 Nov |
|
Indomethacin induced gastropathy in CD18, intercellular adhesion molecule 1, or P-selectin deficient mice. | 1999 Oct |
|
Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. | 1999 Sep |
|
Sulindac inhibits activation of the NF-kappaB pathway. | 1999 Sep 17 |
|
[Effect of carrageenan and indomethacin on the growth of a murine fibrosarcoma]. | 2000 |
|
Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons. | 2000 |
|
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. | 2000 Dec 8 |
|
Characterization of M cell development during indomethacin-induced ileitis in rats. | 2000 Feb |
|
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. | 2000 Feb 11 |
|
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. | 2000 Jan |
|
Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw. | 2000 Jan 14 |
|
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. | 2000 Jul |
|
Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus. | 2000 Jul |
|
Ibuprofen as effective as indomethacin for patent ductus arteriosus. | 2000 Jul 25 |
|
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. | 2000 Jun 15 |
|
Effect of indomethacin on IL-1beta, IL-6 and TNFalpha production by mononuclear cells of preterm newborns and adults. | 2000 Mar |
|
Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. | 2000 Mar |
|
Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. | 2000 May |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. | 2000 Nov |
|
Role of BAX in the apoptotic response to anticancer agents. | 2000 Nov 3 |
|
Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases. | 2000 Nov-Dec |
|
Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice. | 2000 Sep 1 |
|
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. | 2000 Sep 7 |
|
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. | 2000 Sep 8 |
|
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
Increased 15-HPETE production decreases prostacyclin synthase activity during oxidant stress in aortic endothelial cells. | 2001 Feb 1 |
|
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. | 2001 Jan 5 |
|
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. | 2001 Mar |
|
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production. | 2001 Mar 9 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27988363
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m6279
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000086425
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL6
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
258329
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
DTXSID00225256
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
DBSALT001435
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
74252-25-8
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
Indomethacin sodium
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
0IMX38M2GG
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
1294612
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
ALTERNATIVE | |||
|
X-78
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
23674731
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
0IMX38M2GG
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
C47999
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY | |||
|
SUB02677MIG
Created by
admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD